Editorial: BRCA1 and BRCA2 genes mutations screening in sporadic breast cancer patients in Kazakhstan

Main Article Content

Rachel C. Jankowitz
Kelly Z. Knickelbein

Article Details

How to Cite
Jankowitz, R. C., & Knickelbein, K. Z. (2013). Editorial: BRCA1 and BRCA2 genes mutations screening in sporadic breast cancer patients in Kazakhstan. Central Asian Journal of Global Health, 2(1). https://doi.org/10.5195/cajgh.2013.41
Author Biographies

Rachel C. Jankowitz, University of Pittsburgh Cancer Institute; UPMC Magee Women's Cancer Program

Assistant Professor of Medicine

Kelly Z. Knickelbein, UPMC Center for Medical Genetics

Certified Genetic Counselor


Lynch, H.T., et al., Clinical/genetic features in hereditary breast cancer. Breast Cancer Res Treat, 1990. 15(2): p. 63-71.

Pharoah, P.D., et al., Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer, 1997. 71(5): p. 800-9.

Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.2012, 2012.

Foulkes, W.D., Inherited susceptibility to common cancers. N Engl J Med, 2008. 359(20): p. 2143-53.

Pharoah, P.D., et al., Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet, 2002. 31(1): p. 33-6.

Miki, Y., et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994. 266(5182): p. 66-71.

Wooster, R., et al., Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 1994. 265(5181): p. 2088-90.

Woodward, A.M., et al., Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet, 2005. 42(5): p. e31.

Shannon, K.M. and A. Chittenden, Genetic testing by cancer site: breast. Cancer J. 18(4): p. 310-9.

Levy-Lahad, E., et al., Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet, 1997. 60(5): p. 1059-67.

King, M.C., J.H. Marks, and J.B. Mandell, Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 2003. 302(5645): p. 643-6.

Brookes, A.J., The essence of SNPs. Gene, 1999. 234(2): p. 177-86.

Collins, K.J., Physiological variation and adaptability in human populations. Ann Hum Biol, 1999. 26(1): p. 19-38.

Bentley, D.R., The Human Genome Project--an overview. Med Res Rev, 2000. 20(3): p. 189-96.

Lindor, N.M., et al., A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat, 2012. 33(1): p. 8-21.

Chenevix-Trench, G., et al., Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res, 2006. 66(4): p. 2019-27.

Easton, D.F., et al., A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet, 2007. 81(5): p. 873-83.

Goldgar, D.E., et al., Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet, 2004. 75(4): p. 535-44.

Gomez Garcia, E.B., et al., A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res, 2009. 11(1): p. R8.

Spurdle, A.B., et al., Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators. J Clin Oncol, 2008. 26(10): p. 1657-63.

Whiley, P.J., et al., Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. Hum Mutat. 32(6): p. 678-87.

Tavtigian, S.V., et al., Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat, 2008. 29(11): p. 1342-54.

Spurdle, A.B., et al., ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 33(1): p. 2-7.

Thorisson, G.A. and L.D. Stein, The SNP Consortium website: past, present and future. Nucleic Acids Res, 2003. 31(1): p. 124-7.

Iversen, E.S., Jr., et al., A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. Cancer Epidemiol Biomarkers Prev. 20(6): p. 1078-88.

Millot, G.A., et al., A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat.

Plon, S.E., et al., Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat, 2008. 29(11): p. 1282-91.

Lindor, N.M., et al., A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat. 33(1): p. 8-21.